Autoimmune and Inflammatory Rheumatic Diseases

Uses

Risks & contraindications

Where it comes from

Highlighted claims

• The protocol applies no age or sex or gender restrictions to eligible populations. — Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trials
• The review includes more than 35 autoimmune and inflammatory rheumatic diseases. — Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trials
• Many patients with AIRDs do not achieve sustained disease control despite available biologic and small-molecule treatments. — Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trials
• The shared microbiota disturbances across AIRDs justify evaluating them together in one review. — Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trials